May 08, 2018
8th May 2018: Oxford & Manchester, UK and Atlanta, GA. Cytox, a precision medicine testing company which today is commercializing polygenic risk scoring (PRS) and other approaches for assessing genetic risk for developing Alzheimer’s disease, has collaborated with integrated genomics and genetics leader AKESOgen to verify the performance of the Cytox genoBAR™ test with saliva samples.
Read More
Apr 26, 2018
Faecal Immunochemical Testing (FIT) is now an established diagnostic test that identifies the presence of minute quantities of haemoglobin (blood) in the stool, known as faecal occult blood (FOB), which can be an early sign of colorectal cancer. FIT uses antibodies specific to human haemoglobin so is more sensitive and has a greater specificity than the previous qualitative guaiac based methods.
Read More
Apr 26, 2018
Alpha Laboratories Ltd. (Eastleigh, UK) is delighted to have been appointed as the exclusive distributor for Arquer Diagnostics Ltd (“Arquer”) in the UK and Republic of Ireland. Arquer (Sunderland, UK) is an in-vitro diagnostic company developing breakthrough diagnostic tests for the detection of bladder and prostate cancer.
Read More
Apr 24, 2018
Germantown, Maryland, and Hilden, Germany, April 20, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory approval of PartoSure®, which is a novel test for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor.
Read More
Apr 20, 2018
SYDNEY, AUSTRALIA – (April 19, 2018). SpeeDx’s ResistancePlus® MG Positive Control kit has now been listed with the US Food and Drug Administration (FDA) for sale in the United States through the company’s recently incorporated US entity, SpeeDx Inc. The announcement coincides with the FDA registration of the Australian parent company – SpeeDx Pty Ltd – as a Medical Device Manufacturing Establishment, and clinical trials remain on-track for the ResistancePlus MG assay.*
Read More
Apr 17, 2018
Espoo, Finland, April 17th, 2018 - Mobidiag, a Finnish molecular diagnostics company, today announced the launch of Novodiag® Bacterial GE+, a molecular diagnostic test for the simultaneous detection of most common enteric pathogens directly from stool samples. Compatible with the fully automated Novodiag® system launched at the end of 2017, this new disposable cartridge allows direct analysis of a patient sample and delivers comprehensive results in about an hour, compared to days with currentl...
Read More
Mar 20, 2018
Oxford developed prognostic assay for risk of post-surgical recurrence in Stage II colorectal cancer patients to be available throughout China
Read More
Mar 19, 2018
Northampton, UK – 20th March 2018 – HORIBA UK Ltd, Medical announces that in a study recently undertaken and published as a case study by the Oxford Academic Health Science Network (AHSN), its Microsemi CRP point-of-care (POC) analyser was found to enable more rapid clinical decision-making, saving time and reducing costs, in emergency paediatric units.
Read More
Mar 09, 2018
Oxford, UK – 7 March 2018. Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched a new version of its Cytocell® fluorescence in situ hybridisation (FISH) probes website - designed to provide a wealth of information and advice, offer refined functionality, and be easy-to-use. Cytocell is well known for its complete and comprehensive range of FISH probes, exceptional customer support, service and expertise. In the spirit of sharing this expertise and knowledge, OGT has redeve...
Read More
Mar 08, 2018
8 March 2018: Oxford & Manchester, UK. Cytox, an emerging precision medicine leader providing genetic testing for Alzheimer’s disease, is pleased to announce that, in partnership with Cardiff University, the company has been awarded funding by Innovate UK. The award is £800,000 ($1.3m) out of a total project value of £1m ($1.6m) over two years.
Read More
Page 3 of 8 [3]